Back to results

University of Denver

Preclinical Assessment of Immunocal® as a Preventative Treatment for Traumatic Brain Injury (TBI) in a Mouse Model of Closed Head Injury

Abstract

dc:description.abstract

<p>Over the past three decades, traumatic brain injury (TBI) has been considered a "silent epidemic" and recognized as an emergent public health problem by the Centers for Disease Control and Prevention (CDC). TBI is defined as a bump, blow, or jolt to the head that disrupts the normal function of the brain. Due to the debilitating effects and prevalence of TBI, novel preventative treatment regimens are highly desirable in at risk populations. According to the CDC groups disproportionately affected by TBI include athletes, people aged 75+, and service men and women, among others. Here, we investigated a unique whey protein supplement, Immunocal®, to determine its ability to boost resilience of neurons prior to injury. It has been previously described that Immunocal® functions specifically by increasing levels of the essential antioxidant glutathione (GSH). We hypothesize that boosting brain levels of GSH will help ameliorate cognitive, physical, and histopathological indices of brain injury post TBI in a mouse model of closed head impact injury. We found that twice daily oral supplementation with 3.30% Immunocal® for 28-35 days prior to impact significantly improved animal motor coordination and to a lesser extent, cognitive performance. Histopathological results also demonstrated a significant effect on corpus callosum width (axonal myelination) and a decreased presence of degenerating neurons in Immunocal®-treated animals compared to untreated TBI animals. However, no effect was seen in measured clinical effects, or primary injury using MRI analysis. Finally, Immunocal® treatment prevented an ~30% reduction in the brain GSH/GSSG ratio observed in untreated TBI mice. These cumulative data suggest that Immunocal®, while unable to attenuate damage done by the primary injury, was helpful in alleviating secondary injury mechanisms in this TBI mouse model. In the future, this compound could hold promise as a preventative agent for in TBI in certain high risk populations.</p>

Degree

thesis:*
Name thesis:degree_name
M.S.
Level thesis:degree_level
Masters Thesis
Year dc:date.available
2017

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Ignowski, Elizabeth Eugenia
Contributors dc:contributor
  • Daniel A. Linseman, Ph.D.
  • Keith Miller, Ph.D.
  • David Patterson
  • Scott Barbee

Subjects

dc:subject × 8

Rights

dc:rights
Statement dc:rights
  • <p>Copyright is held by the author. User is responsible for all copyright compliance.</p>
Language dc:language
en

Identifiers

dc:identifier.*
Repository record dc:identifier
https://digitalcommons.du.edu/etd/1477
OAI identifier oai:identifier
oai:digitalcommons.du.edu:etd-2477

Chain of custody

source
Harvested from
University of Denver
Base URL
digitalcommons.du.edu/do/oai/
Last updated
2026-07-24
Source record
OAI-PMH GetRecord
citation

Ignowski, Elizabeth Eugenia. Preclinical Assessment of Immunocal® as a Preventative Treatment for Traumatic Brain Injury (TBI) in a Mouse Model of Closed Head Injury. Masters Thesis thesis, 2017. https://digitalcommons.du.edu/etd/1477